KMD111 / KMD Bio - LARVOL DELTA

Development and evaluation of KMD111: A HER2-targeted novel drug delivery system for gastric and breast cancer therapy (AACR 2025) - "It exhibited superior anti-tumor efficacy compared to Enhertu®, Kadcyla®, and Cyramza® and effectively triggered cell cycle arrest and apoptosis activation through a potent anticancer drug. KMD111 demonstrates robust targeting, high therapeutic efficacy, and a favorable safety profile in HER2-expressing gastric and breast cancer models. This innovative approach, leveraging a glutathione-regulated bio-linker for enhanced delivery and tumor specificity, represents a promising foundation for next-generation drug delivery systems targeting HER2-expressing malignancies."

Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2